Article
Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.
Expert opinion on therapeutic targets - 1 Dec 2021
Gonzalez Nazareno, Asad Antonela S, Gómez Escalante José, Peña Agudelo Jorge A, Nicola Candia Alejandro J, García Fallit Matías, Seilicovich Adriana, Candolfi Marianela
Abstract excerpt
INTRODUCTION: Gliomas are stratified by the presence of a hotspot mutation in the enzyme isocitrate dehydrogenase genes (IDH1/2). While mutated IDH (mIDH) correlates with better prognosis, the role of this mutation in antitumor immunity and the response to immunotherapy is not completely understood. Understanding the relationship between the genetic features of these tumors and the tumor immune microenvironment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.